MTVA

MetaVia Inc.

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing peer-reviewed data supporting its anti-fibrotic MASH drug candidate.read more...

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH PR Newswire CAMBRIDGE, Mass., May 20, 2026 CAMBRIDGE, Mass., May 20, 2026 /PRNewswire...

Here are today’s most compelling market narratives. $NTHI, $AMST, $MTVA, $AGYS, $INM, $CODX

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific...

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., May...

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 MetaVia to Present Data Highlighting DA-1726, a...

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity PR Newswire CAMBRIDGE...

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., March 26, 2026 48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss...